Effective targeting of RNA polymerase I in treatment‐resistant prostate cancer

Distinct Mechanisms of Transcription Initiation by RNA Polymerases I and II

(2018) Christoph Engel et al.   Annual Review of Biophysics

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

(2018) Philipp Nuhn et al.   EUROPEAN UROLOGY

The long tail of oncogenic drivers in prostate cancer

(2018) Joshua Armenia et al.   NATURE GENETICS

Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate

(2018) Mark C. Markowski et al.   PROSTATE

Intratumor heterogeneity in prostate cancer

(2018) Shalini S. Yadav et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint

(2018) Ting Wei et al.   Cell Reports

Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting

(2018) Andrea K. Miyahira et al.   PROSTATE

Novel Assay to Detect RNA Polymerase I Activity In Vivo

(2017) Gunes Guner et al.   MOLECULAR CANCER RESEARCH

BMH-21 inhibits viability and induces apoptosis by p53-dependent nucleolar stress responses in SKOV3 ovarian cancer cells

(2017) Xinxu Fu et al.   ONCOLOGY REPORTS

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours

(2017) Hong Xu et al.   Nature Communications

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer

(2016) Richard J. Rebello et al.   CLINICAL CANCER RESEARCH

Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer

(2015) Gretchen K. Hubbard et al.   CANCER RESEARCH

DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response

(2015) Laureen Colis et al.   Oncotarget

A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity

(2014) Karita Peltonen et al.   CANCER CELL

p53 and ribosome biogenesis stress: The essentials

(2014) Lior Golomb et al.   FEBS LETTERS

Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer

(2014) P. J. Toren et al.   MOLECULAR CANCER THERAPEUTICS

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression

(2013) Jeffry L. Dean et al.   CURRENT DRUG TARGETS

Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner

(2013) Swagat Ray et al.   GENE

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Force spectroscopy reveals the DNA structural dynamics that govern the slow binding of Actinomycin D

(2012) Thayaparan Paramanathan et al.   NUCLEIC ACIDS RESEARCH

Revisiting the Nucleolus: From Marker to Dynamic Integrator of Cancer Signaling

(2012) D. Ruggero   Science Signaling

Overexpression of ribosomal RNA in prostate cancer is common but not linked to rDNA promoter hypomethylation

(2011) M Uemura et al.   ONCOGENE

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

(2010) Denis Drygin et al.   CANCER RESEARCH

Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels

(2010) Kaspar Burger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Nucleolus under Stress

(2010) Séverine Boulon et al.   MOLECULAR CELL

Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents

(2010) Karita Peltonen et al.   PLoS One